Fosfomycin (calcium)

• Description :

  Fosfomycin (MK-0955) calcium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin calcium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria[1][2].

• CAS Number :

  [26016-98-8]

• Product Name Alternative :

  MK-​0955 (calcium)

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Antibiotic; Bacterial

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Fosfomycin-calcium.html

• Purity :

  98.0

• Solubility :

  H2O : 50 mg/mL (ultrasonic; adjust pH to 2 with HCl)

• Smiles :

  C[C@H]1[C@@H](P([O-])([O-])=O)O1.[Ca+2]

• Molecular Formula :

  C3H5CaO4P

• Molecular Weight :

  176.12

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel) . 2017 Oct 31;6 (4) . pii: E24.|[2]Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29 (2) :321-47.|[3]Inouye S, et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn. 1982 Sep. 5 (9) :659-69.|[4]Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5 (12) :941-50.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  Front Cell Infect Microbiol. 2019 Jul 15:9:253.|J Med Microbiol. 2019 Mar;68 (3) :493-502.|ACS Infect Dis. 2024 Aug 9;10 (8) :2961-2977.|Antibiotics (Basel) . 2021 Sep 14;10 (9) :1110.|bioRxiv. 2024 May 10.|bioRxiv. 2025 January 19.|J Antibiot (Tokyo) . 2025 Mar;78 (4) :265-273.|MedComm (2020) . 2025 Jan 8;6 (1) :e70046.|Molecules. 2025 Mar 9;30 (6) :1224.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Infect Genet Evol. 2025 Sep:133:105780.|Microb Pathog. 2025 Oct 25.|Microbiol Spectr. 2025 Sep 2;13 (9) :e0152125.